1049020-11-2
1049020-11-2
Chemical Structure
DOTA-GA2(tBu)4
- CAS No.: 1049020-11-2
- Formula:C38H68N4O12
- Molecular Weight:772.97
InChIKey: LSKSMUUMZJWJBB-UHFFFAOYSA-N
SMILES: O=C(CCC(N1CCN(CCN(C(CCC(O)=O)C(OC(C)(C)C)=O)CCN(CC1)CC(OC(C)(C)C)=O)CC(OC(C)(C)C)=O)C(OC(C)(C)C)=O)O
Biological Activity: DOTA-GA2 (tBu) 4 is a protected DOTA-based chelator precursor that can bind to radionuclides. DOTA-GA2 (tBu) 4 can be used to prepare radionuclide drugs, such as DOTADG-containing Exendin-4 (HY-13443) derivatives[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DOTA-GA2(tBu)4 | DOTA-GA2 (tBu) 4 is a protected DOTA-based chelator precursor that can bind to radionuclides. DOTA-GA2 (tBu) 4 can be used to prepare radionuclide drugs, such as DOTADG-containing Exendin-4 (HY-13443) derivatives. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Iikuni S, et al. Development of an In-Labeled Glucagon-Like Peptide-1 Receptor-Targeting Exendin-4 Derivative that Exhibits Reduced Renal Uptake. Molecular pharmaceutics. 2022 Mar 07;19(3):1019-1027.
- [2]. Hasegawa T, et al. Development of Novel Radiotheranostic Ligand with Positively Charged Unit Targeting Prostate-Specific Membrane Antigen. Journal of medicinal chemistry. 2025 May 22;68(10):10190-10202. [Content Brief]
- [3]. Nakashima K, et al. Systematic Investigation of Fatty Acids with Different Carbon-Chain Length as Albumin Binder to Improve Tumor Accumulation of Radioligands. Bioconjugate chemistry. 2026 Jul 15;37(7):1377-1385.
